Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection

NCT01292824 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT01292824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Lead sponsor
University of Birmingham
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2011
Completion date
May 31, 2013
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

evidence of liver transplantation, hepatitis c